Literature DB >> 15979322

Incidence of cancer after immunosuppressive treatment for heart transplantation.

Giovanbattista Ippoliti1, Mauro Rinaldi, Carlo Pellegrini, Mario Viganò.   

Abstract

Prolonged or intensive immunosuppressive therapy used after organ transplantation is complicated by an increased incidence of cancer. Striking differences in incidence are observed in heart and heart-lung transplant recipients when compared with renal transplant patients. The most significant increase was in the incidence of lymphomas in cardiac versus renal patients. Moreover, a two-fold greater increase of all neoplasms was found in cardiac recipients, with nearly a six-fold increase in visceral tumors. Several factors may account for these differences. In cardiac allograft recipients, intensive immunosuppression is frequently used to reverse acute rejection and the highest number of cardiac transplants was performed in the era of polypharmacy, usually consisting of triple therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979322     DOI: 10.1016/j.critrevonc.2005.03.013

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients.

Authors:  Yixin Jia; Xu Meng; Yan Li; Chunlei Xu; Wen Zeng; Yuqing Jiao; Wei Han
Journal:  Exp Ther Med       Date:  2018-09-10       Impact factor: 2.447

2.  Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients.

Authors:  Nicolás Manito; Juan F Delgado; María G Crespo-Leiro; José María Arizón; Javier Segovia; Francisco González-Vílchez; Sònia Mirabet; Ernesto Lage; Domingo Pascual-Figal; Beatriz Díaz; Jesús Palomo; Gregorio Rábago; Marisa Sanz; Teresa Blasco; Eulàlia Roig
Journal:  World J Transplant       Date:  2015-12-24

3.  Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.

Authors:  Mieke Van Hemelrijck; Lars Holmberg; Hans Garmo; Niklas Hammar; Göran Walldius; Elisa Binda; Mats Lambe; Ingmar Jungner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-02-04       Impact factor: 4.254

4.  Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection.

Authors:  Giovanbattista Ippoliti; Andrea Maria D'Armini; Marco Lucioni; Mazen Marjieh; Mario Viganò
Journal:  Biologics       Date:  2012-10-04

5.  Grover's Disease after Heart Transplantation: A Case Report.

Authors:  Giovanbattista Ippoliti; Marco Paulli; Marco Lucioni; Andrea Maria D'Armini; Marinella Lauriola; Rany Mahrous Haleem Saaleb
Journal:  Case Rep Transplant       Date:  2012-12-20

6.  Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?

Authors:  William B Yates; Peter J McCluskey; Denis Wakefield
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-05-31

7.  Metastatic Lung Adenocarcinoma Harboring an EGFR-Activating Mutation in a Heart Transplant Recipient.

Authors:  Elizabeth Zambrano Mendoza; Cheng Tzu Yen; Tiago Kenji Takahashi; Gustavo Faibischew Prado; Marcelo Luiz Balancin; Gilberto de Castro
Journal:  J Glob Oncol       Date:  2017-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.